← Moleculin Biotech, Inc. (MBRX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Moleculin Biotech, Inc. (MBRX)
Pharmaceutical Preparations · market cap $11M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
6
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Moleculin Biotech (MBRX) is a micro-cap pharmaceutical company with 17 employees and an ~$11M market cap, built around Liposomal Annamycin (L-Annamycin) in combination with Cytarabine as its lead asset in Phase 3 for Acute Myeloid Leukemia (AML). A data readout was reported as positive on 2026-06-30, though no detailed trial results are provided in the available facts. The company has $10.3M in cash, representing approximately 5 months of runway, creating near-term financing urgency.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Liposomal Annamycin (L-Annamycin) | Phase 2 | Sarcoma,Soft Tissue |
| Liposomal Annamycin | Phase 2 | Leukemia, Myeloid, Acute |
| MOL4239 | Phase 2 | Psoriasis |
| Liposomal Annamycin Injection in combination with Cytarabine Injection | Phase 3 | Acute Myeloid Leukaemia (AML) |
| STAT3 Inhibitor WP1066 | Phase 2 | Glioblastoma, IDH-Wildtype |
| Liposomal Annamycin for Injection in combination with Cytarabine Injection | Phase 3 | Acute Myeloid Leukaemia (AML) |
Price & technical context
3-month
-68.5%
6-month
-83.3%
12-month
-29.5%
52-wk range
$3.31–$96.20
vs 50-day MA
-22.3%
vs 200-day MA
-79.4%
Realized vol
350.1%
Max drawdown
-98.6%
Daily closes through 2026-10-27. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MBRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.